Feed / RMD

ResMed Inc.

RMD

Healthcare · 222.69 -0.1% today

Isolated · not yet confirmedMarket checked 1 Oct, 11:40 GMT-4

Market read

No connected market move is active around ResMed Inc..

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company-0.1% todayVolume comparison unavailable
Market groupNo active group readNo durable group available
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • Cash used for acquisitions, including Noctrix, was a major contributor to the increase in investing cash outflow.
  • R&D spending increased, with management attributing the rise primarily to employee-related costs.

Invalidation: The isolated read changes if RMD's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Instruments & Supplies

No new filing conclusion is available. 0 of 0 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • Cash used for acquisitions, including Noctrix, was a major contributor to the increase in investing cash outflow.
  • R&D spending increased, with management attributing the rise primarily to employee-related costs.

Company research

Understand the business, not just the ticker

As of Oct 1, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations615
Usable filing statements92
Verified relationships5
Evidence supporting the case
  • Latest annual revenue changed +9.9% year over year.
  • Demand and volume has repeated favorable evidence across 5 filings.
  • Product pipeline and R&D has repeated favorable evidence across 5 filings.
Evidence challenging the case
  • Credit and interest rates has repeated adverse evidence across 5 filings.
Questions before a position
  • P/E is 16% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 52% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 30, 2026

221.15
6m-1.5%12m-18.4%24m-8.1%
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2022-06-30$3.6B+11.9%$5.30+0.4%
2023-06-30$4.2B+18.0%$6.09+0.3%
2024-06-30$4.7B+10.9%$6.92+0.1%
2025-06-30$5.1B+9.8%$9.51-0.1%
2026-06-30$5.7B+9.9%$10.43-0.9%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 5 filings
“We recorded interest income, net, of $50 million for the year ended June 30, 2026 compared to interest income, net, of $4 million for the year ended June 30, 2025 due to lower debt levels following the repayment of our revolving credit facility, gains recogni…”
10-K · Aug 13, 2026 ↗
Demand and volumemixed · 5 filings
“The constant currency increase in device and mask sales in Rest of World was primarily attributable to increased demand and unit sales across our sleep health, partially offset by lower unit sales of our life support devices.”
10-K · Aug 13, 2026 ↗
Product pipeline and R&Dpositive · 5 filings
“The constant currency increase in research and development expenses was primarily due to increases in employee-related costs.”
10-K · Aug 13, 2026 ↗
Legal and regulatory exposuremixed · 3 filings
“Our total contributions to the plan were $ 5 million, $ 4 million and $ 4 million in fiscal 2026, 2025 and 2024, respectively.”
10-K · Aug 13, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales 5.7× · EV/sales 5.5×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

222.69-0.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 1 Oct, 11:40 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for RMD. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for RMD. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind RMD

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

GLPFiling-linked namecompetitorAug 8, 2025 ▾

“Competition Global competition for sales of our products and services is intense.”

Depended on by

INSPInspire Medical Systems, Inc.competitorFeb 13, 2026 ▾

“Our specific PAP-related competitors include ResMed Inc., Philips BV, Fisher & Paykel Healthcare Corporation Limited, and various regional and new-entrant manufacturers.”

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

RMD is currently a Follower in the organic co-movement group Unknown Theme. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for RMD; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.